2025/2026 INTERIM RESULTS INVESTORS PRESENTATION 2025.11.25 1H2026 HIGHLIGHTS Solid trajectory with sustained profitability | Revenue | | | Gross profit margin | | | --- | --- | --- | --- | --- | | HK$38,986 | million | On constant fx | 30.5% | 1H2025 31.4% | | 1.1% | | 0.5% | | | | Operating profit | | | Operating profit margin | | | HK$6,823 | million | 0.7% | 17.5% | 1H2025 17.2% | | Profit attributable to shareholders | | | Dividend per share | | | HK$2,534 | million | 0.1% | HK$0.22 | Payout ratio 85.7 ...

Financial Performance - Vitasoy's revenue decreased by 6% from HKD 3,443 million to HKD 3,227 million [7] - Gross profit decreased by 7% from HKD 1,777 million to HKD 1,648 million [7] - Profit from operations decreased by 4% from HKD 257 million to HKD 247 million [7] - EBITDA decreased by 4% from HKD 496 million to HKD 479 million [7] - Profit to shareholders increased by 1% from HKD 171 million to HKD 172 million [7] - Basic earnings per share increased by 2% from HKD 15.9 cents to HKD 16.2 cents [9] Capital Expenditure and Cash Position - Capital expenditure increased from HKD 45 million to HKD 57 million [11] - The company's net cash position slightly increased from HKD 1,268 million to HKD 1,274 million [13] Key Ratios - Gearing remained stable at 20% [15] - ROCE remained stable at 14% [15] - Dividend per share remained at HK4.0 cents [15] Business Performance by Geography - China's total revenue decreased by 7% to HKD 2,890 million [24, 28] and operating profit decreased by 14% to HKD 326 million [26, 28] - Chinese Mainland revenue decreased by 9% to HKD 1,778 million [24, 30, 32] and operating profit decreased by 12% to HKD 191 million [26, 30, 32] - Hong Kong Operation revenue decreased by 4% to HKD 1,112 million [24, 31, 38] and operating profit decreased by 15% to HKD 135 million [26, 31, 38] - Australia & NZ revenue increased by 2% to HKD 279 million [24, 43], but experienced an operating loss of HKD 22 million [26, 43] - Singapore revenue increased by 2% to HKD 57 million [24, 48], but experienced an operating loss of HKD 1 million [26, 48]

Financial Performance - The company's revenue increased by 2.1% year-over-year, reaching RMB 11,108 million in 1H FY25 compared to RMB 10,877 million in 1H FY24[5] - Gross profit margin decreased by 110 basis points from 47.3% in 1H FY24 to 46.2% in 1H FY25, influenced by increased costs of whole milk powder and product mix[5] - Operating profit decreased by 11.0% from RMB 2,541 million in 1H FY24 to RMB 2,261 million in 1H FY25[5] - Profit attributable to owners of the company decreased by 7.8% from RMB 1,863 million in 1H FY24 to RMB 1,717 million in 1H FY25, with an income tax rate of 23.0%[5] Revenue Breakdown by Product Category - Rice crackers revenue increased to RMB 2,130 million in 1H FY25 from RMB 2,057 million in 1H FY24[11], with sales volume up by mid-single digits[14] - Dairy and beverage revenue decreased slightly to RMB 5,941 million in 1H FY25 from RMB 6,009 million in 1H FY24[15], while beverage sales doubled[15] - Snack food revenue increased to RMB 2,940 million in 1H FY25 from RMB 2,731 million in 1H FY24[16], with ice product sub-category increasing by mid-double digits[34] Channel Performance - Emerging channels and snack food retail channels experienced high-speed growth[5, 14, 15, 16, 33, 34] - Snack food retail channels account for approximately 15% of the group's revenue[37] - Emerging channels account for over 10% of the group's revenue[37] - Overseas market revenue increased by low-single digits and accounts for high-single digits of the group's revenue[37] Expenses and Working Capital - Operating expenses increased by 10.6% from RMB 2,894 million in 1H FY24 to RMB 3,202 million in 1H FY25, driven by increased A&P expenses[5, 18] - Distribution costs increased from RMB 1,369 million in 1H FY24 to RMB 1,550 million in 1H FY25[21], with distribution costs accounting for 14.0% of revenue in 1H FY25, up from 12.6% in 1H FY24[19] - Inventory increased from RMB 2,576 million on March 31, 2025, to RMB 2,748 million on September 30, 2025[26], with inventory turnover days increasing from 74 to 80 days[25]

November 2025 2025 年 11 月 1 Sa Sa International Holdings Limited 莎莎國際控股有限公司 (Stock Code 股份代號：178) 財務表現 財務狀況 財務表現 Financial Performance P.4-6 財務狀況 Financial Position For the six months ended 30 September 2025 截至2025年9月30日止六個月中期業績 業務回顧 Business Review P.10-14 策略及展望 Strategy & Outlook P. 16 2 Financial Performance Financial Position Business Review 業務回顧 Strategy & Outlook 策略及展望 P.8 3 Improved Consumer Sentiment in HK and Macau Drives Group's Offline Sales Up by 8.3% YoY; Online Sales Remained Flat, While Profi ...

Q2FY26 Earnings Announcement November 20, 2025 2025 Lenovo Internal. All rights reserved. 2025 Lenovo Internal. All rights reserved. Forward-Looking Statement This presentation contains "forward-looking statements", which are statements that refer to the expectations and plans for the future and include, without limitation, statements regarding Lenovo's future results of operations, financial condition or business prospects as well as other statements based on projections, estimates and assumptions. In some ...

Financial Performance - Revenue for 1-9/2025 was RMB 19,891 million, a decrease of 12.3% compared to RMB 22,686 million in 1-9/2024[27] - Gross profit for 1-9/2025 was RMB 13,049 million, down 18.4% from RMB 15,985 million in 1-9/2024[27] - Gross profit margin decreased by 4.9 percentage points, from 70.5% in 1-9/2024 to 65.6% in 1-9/2025[27] - R&D expenses increased by 7.9%, from RMB 3,880 million in 1-9/2024 to RMB 4,185 million in 1-9/2025[27] - Reported profit attributable to shareholders decreased by 7.1%, from RMB 3,778 million in 1-9/2024 to RMB 3,511 million in 1-9/2025[27] - Underlying profit attributable to shareholders decreased by 23.0%, from RMB 3,999 million in 1-9/2024 to RMB 3,079 million in 1-9/2025[27] - Finished drugs revenue decreased by 17.2%, from RMB 18,670 million to RMB 15,450 million[28] - Revenue from oncology decreased significantly by 56.8%, from RMB 3,809 million to RMB 1,645 million[29] - Revenue from nervous system decreased by 21.6%, from RMB 7,234 million to RMB 5,669 million[29] - License fee revenue was RMB 1,540 million in 1-9/2025, compared to no revenue in 1-9/2024[29] R&D and Regulatory Updates - 3 new drugs were approved[5] - 5 breakthrough therapy designations were received[5] - 12 new pivotal clinical trials were initiated[7] - 52 IND approvals were obtained, including 42 in China and 10 in North America[7] BD and Shareholder Returns - License-out agreements were made for SYS6005, Irinotecan Liposome Injection, SYH2086 and strategic collaboration with AstraZeneca[9, 115] - A total of HK$300 million worth of shares have been repurchased this year[8] - The 2025 interim dividend is HK14 cents per share[8] R&D Pipeline Highlights - Anbenitamab injection co docetaxel treatment of 1L HER2+ relapse/metastasis breast cancer was published in Cancer Communications, with ORR of 76.4% and mPFS of 27.7m[37] - SYS6091 for injection has been granted as BTD by NMPA for the treatment of platinum resistant recurrent epithelial ovarian cancer, primary peritoneal cancer, or whole population of patients with fallopian tube cancer and HER2-positive advanced colorectal cancer[45] - JMT101+ Irinotecan has been granted as BTD by NMPA for the treatment of RAS, RAF, EGFR ECD and PIK3CA exon 20 wild-type advanced colorectal cancer after failure of standard treatment in second-line or beyond[51] - The company has approximately 200 innovative drugs and new formulations[4, 96]

Financial Performance - Group revenue reached RMB 113.1 billion, a YoY increase of 22.3%[11] - Gross profit margin increased to 22.9%, up 2.5 percentage points YoY[11] - Adjusted net profit reached RMB 11.3 billion, a significant YoY increase of 80.9%[11] - Smart EV, AI and other new initiatives revenue reached RMB 29.0 billion, a substantial YoY increase of 199.2%[11] Smartphone and AIoT Business - Global smartphone shipments ranked among the top 3 for 21 consecutive quarters, with a market share of 13.6%[14] - Premium smartphone sales in Chinese Mainland increased to 24.1% of total smartphone units sold, a YoY increase of 4.1 percentage points[14] - IoT and lifestyle products revenue reached RMB 27.6 billion, up 5.6% YoY[85] Smart EV Initiatives - Delivered 108,796 Smart Electric Vehicles, representing a YoY increase of 173.4%[18] - Smart EV sales revenue reached RMB 28.3 billion, up 197.9% YoY[89] User Growth and AI - Global MAU reached 741.7 million[21] - Number of connected devices reached 1,035.5 million[26] R&D Investment - R&D expenses reached RMB 9.1 billion in Q3 2025[31]

Financial Performance - Revenue for Q3 2025 was $2,382 million, up 7.8% QoQ from $2,209 million in 2Q25 and up 9.7% YoY from $2,171 million in 3Q24 [5, 11] - Gross margin was 22.0%, compared to 20.4% in 2Q25 and 20.5% in 3Q24 [6, 12] - Profit from operations was $351 million, compared to $151 million in 2Q25 and $170 million in 3Q24 [7, 13] - Profit attributable to SMIC was $192 million, compared to $132 million in 2Q25 and $149 million in 3Q24 [8, 14] - EBITDA was $1,430 million, compared to $1,129 million in 2Q25 and $1,157 million in 3Q24 [9, 15] Capital Structure and Cash Flow - Total cash on hand was $11,385 million as of September 30, 2025 [18] - Net cash generated from operating activities was $941 million for the three months ended September 30, 2025 [22] Revenue Breakdown - China accounted for 86.2% of total revenue in 3Q25 [26] - 12-inch wafers accounted for 77.0% of wafer revenue in 3Q25 [32] Capacity and Utilization - Monthly capacity reached 1,022,750 (standard logic 8-inch equivalent wafers) in 3Q25 [36] - Utilization rate was 95.8% in 3Q25 [36] Guidance - Revenue for 4Q 2025 is expected to be flat to +2% QoQ [40] - Gross margin for 4Q 2025 is guided to be between 18% and 20% [40]

2025 Third Quarter Results Presentation November 13, 2025 1 Cautionary Note This presentation may contain forward-looking statements relating to the forecasts, targets, outlook, estimates of financial performance, opportunities, challenges, business developments, business plans and growth strategies of Tencent Holdings Limited (the "Company" or "Tencent") and its group companies. These forward-looking statements are based on information currently available to Tencent and are stated here on the basis of the ...

Financial Performance - VTech's revenue decreased by 90% to $9911 million from $10897 million[5] - Gross profit decreased by 81% to $3158 million[5] - Profit attributable to shareholders of the company decreased by 145% to $747 million[5] - Basic earnings per share decreased by 147% to 295 US cents[5] Regional Revenue - North America revenue decreased by 121% to $3983 million, accounting for 402% of group revenue[7] - Europe revenue decreased by 72% to $4290 million, representing 433% of group revenue[7] - Asia Pacific revenue decreased by 56% to $1504 million, making up 152% of group revenue[7] - Other Regions revenue decreased by 113% to $134 million, which is 13% of group revenue[7] Product Line Performance in North America - ELPs revenue fell 254% to $1670 million[17] - TEL products revenue fell 80% to $848 million[23] - CMS revenue increased 69% to $1465 million[27] Product Line Performance in Europe - ELPs revenue increased by 55% to $1446 million[30] - TEL products revenue increased 245% to $1052 million[40] - CMS revenue decreased 255% to $1792 million[44] Product Line Performance in Asia Pacific - ELPs revenue decreased 56% to $334 million[50] - TEL products revenue decreased 82% to $89 million[50] - CMS revenue fell 54% to $1081 million[54]